Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, ...

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

The MHRA has approved tisotumab vedotin for adults with recurrent or metastatic cervical cancer, offering a new option after ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...